Darren S. Cline - 09 Jan 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Chief Commercial Officer
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol: XENE
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 18:53:13 UTC
Previous filing: 24 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cline Darren S	Chief Commercial Officer	3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA	/s/ Nathaniel Adams, Attorney-in-fact	09 Jan 2026	0001633639

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Share Option (Right to Buy)	Award	$0	+40,000		$0.000000	40,000	09 Jan 2026	Common Shares	40,000	$42.15	Direct	F1
transaction	XENE	Restricted Share Units	Award	$0	+20,000		$0.000000	20,000	09 Jan 2026	Common Shares	20,000	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2	Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.